Preparing for future pandemics
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats.
Find out more
Latest News
Latest News
Richard Hatchett reflects on a “banner year for viruses” and looks ahead to 2025
In his end-of-year message, CEPI's CEO, Dr Richard Hatchett, reflects on a "banner year for viruses" and explores the trends, innovations and technologies that are shaping the future of global health.
Valneva expands access to Asia for its chikungunya vaccine with Serum
The collaboration to support broader vaccine access to the region falls within the agreement between Valneva and CEPI with co-funding from the EU.
Establishing vaccine safety benchmarking in Africa for African vaccines
Consortium is set to further establish a vaccine safety evidence-generation network in Africa, seeking to understand prevalence of anticipated adverse events specifically relevant to African populations.
The Pneumoviruses and Adenoviruses
Among these viruses is a pervasive pathogen that infects nearly all babies and children worldwide at least once— sometimes twice—before they reach the age of two
Scientists launch largest-ever study tracking chikungunya burden in East Africa
Led by the University of Oxford, researchers are set to investigate the number of children and adults affected by chikungunya in Kenya and Tanzania.
Transatlantic scientists to transition traditional vaccine development onto rapid-response platform for faster outbreak control
Partnership could speed up parts of the vaccine development process by several months and save over £1 million in development costs
CEPI and Accumulus Synergy team up to enhance information equity and accelerate access to vaccines
Accumulus' cloud-based data-sharing platform could speed up access to vaccines and other health technologies by accelerating regulatory review.
Dr Amadou Sall to join CEPI as Executive Director of Manufacturing and Supply Chain
Dr Sall will join CEPI on 1 June 2025 upon completion of his tenure as CEO of Senegal’s Institut Pasteur de Dakar (IPD).
The Rhabdoviruses
The most fearsome Rhabdovirus causes a killer infection which makes its victims foam at the mouth
New project aims to bolster global vaccine preparedness against SARS-CoV-1 and SARS-CoV-2
Project will help to ensure the availability of antibody reagents for the development of vaccines against SARS-CoV-1 and SARS-CoV-2.
Latest News
We want to create a world in which epidemics and pandemics are no longer a threat to humanity.
CEPI is working to galvanise the development of new vaccines and other biologic countermeasures against diseases that could cause the next devastating epidemic or pandemic.
Our approach
Research and development
CEPI is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.
Calls for Proposals
Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Manufacturing and supply chain
CEPI is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.
The Viral Most Wanted
Join CEPI’s disease detectives as they investigate the viral families that have threatened human life for centuries.
$12.5 trillion
IMF’s estimate cost of the COVID-19 pandemic to the global economy through 2024
50+
Number of CEPI-supported vaccine candidates or platform technologies.
$2.8 billion
The minimum average cost to progress one vaccine each against 11 WHO priority infectious diseases
Emerging infectious diseases affect us all. They do not respect borders.
A commitment to equitable access informs every aspect of our work. It is core to CEPI’s vision of a world in which epidemics and pandemics are no longer a threat to humanity.
CEPI take a systems approach to equitable access, seeking to enable equitable access within a broad ecosystem of national and international public and private sector partners and networks.
We work towards this goal by enabling equitable access directly through financial investments and partnerships, and indirectly through advocacy and policy contributions to the evolving ecosystem.
